EP1344526A4 - Preventives/ermedies for inflammatory airway diseases - Google Patents
Preventives/ermedies for inflammatory airway diseasesInfo
- Publication number
- EP1344526A4 EP1344526A4 EP01271858A EP01271858A EP1344526A4 EP 1344526 A4 EP1344526 A4 EP 1344526A4 EP 01271858 A EP01271858 A EP 01271858A EP 01271858 A EP01271858 A EP 01271858A EP 1344526 A4 EP1344526 A4 EP 1344526A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- preventives
- airway
- airway diseases
- inflammatory airway
- halogeno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002757 inflammatory effect Effects 0.000 title abstract 3
- 230000003449 preventive effect Effects 0.000 title abstract 3
- 208000023504 respiratory system disease Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000037883 airway inflammation Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000003909 | 2000-12-22 | ||
JP2000390941 | 2000-12-22 | ||
PCT/JP2001/011264 WO2002051422A1 (en) | 2000-12-22 | 2001-12-21 | Preventives/ermedies for inflammatory airway diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1344526A1 EP1344526A1 (en) | 2003-09-17 |
EP1344526A4 true EP1344526A4 (en) | 2005-03-16 |
EP1344526B1 EP1344526B1 (en) | 2008-05-28 |
Family
ID=18857198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01271858A Expired - Lifetime EP1344526B1 (en) | 2000-12-22 | 2001-12-21 | Preventives/remedies for inflammatory airway diseases |
Country Status (16)
Country | Link |
---|---|
US (1) | US7214672B2 (en) |
EP (1) | EP1344526B1 (en) |
JP (1) | JP3691487B2 (en) |
KR (1) | KR100833157B1 (en) |
CN (2) | CN1481246A (en) |
AR (2) | AR031969A1 (en) |
AT (1) | ATE396733T1 (en) |
CA (1) | CA2438799C (en) |
DE (1) | DE60134267D1 (en) |
DK (1) | DK1344526T3 (en) |
ES (1) | ES2305029T3 (en) |
MX (1) | MXPA03005660A (en) |
PE (1) | PE20020793A1 (en) |
PT (1) | PT1344526E (en) |
TW (1) | TWI290145B (en) |
WO (1) | WO2002051422A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
GB0019172D0 (en) * | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
CA2417825C (en) * | 2000-08-05 | 2008-07-22 | Glaxo Group Limited | 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US7291608B2 (en) * | 2001-04-30 | 2007-11-06 | Glaxo Group Limited | Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α |
US20040248867A1 (en) * | 2001-06-12 | 2004-12-09 | Keith Biggadike | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
JP3691459B2 (en) * | 2002-06-14 | 2005-09-07 | 久光メディカル株式会社 | Powder inhalant composition |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
EP1645266A1 (en) * | 2004-10-08 | 2006-04-12 | Hisamitsu Medical Co., Ltd. | Aqueous suspension for nasal drops |
GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
EP2111861A1 (en) | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639434A (en) * | 1967-02-02 | 1972-02-01 | Boots Pure Drug Co Ltd | 17-acyloxysteroids and their manufacture |
US4024131A (en) * | 1974-03-27 | 1977-05-17 | Plurichemie Anstalt | 16-Methyl-9α-halo steroid esters, ethers and preparation thereof |
US4655971A (en) * | 1981-08-04 | 1987-04-07 | Plurichemie Anstalt | Novel process for the preparation of steroidal esters |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933168A (en) * | 1975-05-27 | 1990-06-12 | Syntex Pharmaceuticals International Limited | Stable, crystalline flunisolide |
JPH07116215B2 (en) * | 1989-04-19 | 1995-12-13 | エスエス製薬株式会社 | Novel steroid compound |
PE44995A1 (en) * | 1994-01-27 | 1995-12-18 | Schering Corp | MOMETASONE FUROATE FOR THE TREATMENT OF LUNG DISEASES AND RESPIRATORY TRACT |
-
2001
- 2001-12-21 DK DK01271858T patent/DK1344526T3/en active
- 2001-12-21 AT AT01271858T patent/ATE396733T1/en active
- 2001-12-21 CN CNA018210422A patent/CN1481246A/en active Pending
- 2001-12-21 ES ES01271858T patent/ES2305029T3/en not_active Expired - Lifetime
- 2001-12-21 US US10/451,061 patent/US7214672B2/en not_active Expired - Lifetime
- 2001-12-21 PT PT01271858T patent/PT1344526E/en unknown
- 2001-12-21 EP EP01271858A patent/EP1344526B1/en not_active Expired - Lifetime
- 2001-12-21 KR KR1020037007282A patent/KR100833157B1/en active Protection Beyond IP Right Term
- 2001-12-21 JP JP2002552566A patent/JP3691487B2/en not_active Expired - Lifetime
- 2001-12-21 MX MXPA03005660A patent/MXPA03005660A/en active IP Right Grant
- 2001-12-21 CN CNA2009100064252A patent/CN101518537A/en active Pending
- 2001-12-21 CA CA002438799A patent/CA2438799C/en not_active Expired - Lifetime
- 2001-12-21 WO PCT/JP2001/011264 patent/WO2002051422A1/en active IP Right Grant
- 2001-12-21 TW TW090131849A patent/TWI290145B/en not_active IP Right Cessation
- 2001-12-21 DE DE60134267T patent/DE60134267D1/en not_active Expired - Lifetime
- 2001-12-26 AR ARP010106024A patent/AR031969A1/en not_active Application Discontinuation
- 2001-12-26 PE PE2001001303A patent/PE20020793A1/en not_active Application Discontinuation
-
2014
- 2014-09-23 AR ARP140103518A patent/AR097737A2/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639434A (en) * | 1967-02-02 | 1972-02-01 | Boots Pure Drug Co Ltd | 17-acyloxysteroids and their manufacture |
US4024131A (en) * | 1974-03-27 | 1977-05-17 | Plurichemie Anstalt | 16-Methyl-9α-halo steroid esters, ethers and preparation thereof |
US4655971A (en) * | 1981-08-04 | 1987-04-07 | Plurichemie Anstalt | Novel process for the preparation of steroidal esters |
Also Published As
Publication number | Publication date |
---|---|
US20040053904A1 (en) | 2004-03-18 |
CA2438799C (en) | 2009-09-01 |
TWI290145B (en) | 2007-11-21 |
CN101518537A (en) | 2009-09-02 |
EP1344526B1 (en) | 2008-05-28 |
AR097737A2 (en) | 2016-04-13 |
KR20030064414A (en) | 2003-07-31 |
WO2002051422A1 (en) | 2002-07-04 |
PT1344526E (en) | 2008-06-18 |
JPWO2002051422A1 (en) | 2004-04-22 |
MXPA03005660A (en) | 2004-12-03 |
DE60134267D1 (en) | 2008-07-10 |
AR031969A1 (en) | 2003-10-08 |
KR100833157B1 (en) | 2008-05-28 |
EP1344526A1 (en) | 2003-09-17 |
CN1481246A (en) | 2004-03-10 |
CA2438799A1 (en) | 2002-07-04 |
ES2305029T3 (en) | 2008-11-01 |
PE20020793A1 (en) | 2002-09-06 |
ATE396733T1 (en) | 2008-06-15 |
DK1344526T3 (en) | 2008-09-15 |
JP3691487B2 (en) | 2005-09-07 |
US7214672B2 (en) | 2007-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1344526A4 (en) | Preventives/ermedies for inflammatory airway diseases | |
GEP20043315B (en) | Non-Peptide GnRH Agents, Methods For Their Preparation and Use Thereof | |
HRP20050781B1 (en) | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels | |
CA2408142A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
WO2001032596A8 (en) | Phenoxy carboxylic acid compounds and compositions for delivering active agents | |
ATE323498T1 (en) | OLIGOSACCHARIDEALDONIC ACID AND ITS TOPICAL ADMINISTRATION | |
DE60027463D1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING RESVERATROL AND USES THEREOF | |
TW234691B (en) | ||
CA2339597A1 (en) | Anti-inflammatory analgesic preparations comprising 3-o-ascorbic acid derivatives | |
WO2001030802A3 (en) | Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies | |
EP1057484A4 (en) | Cell death inhibitors | |
MXPA02002452A (en) | Preventive and therapeutic agents for eye diseases. | |
EP1224932A4 (en) | Drugs inhibiting cell death | |
CA2417935A1 (en) | Anti-inflammatory medicament | |
BR0015177A (en) | benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent | |
IT1196041B (en) | (8S) -8-FLUOROERITROMICINE, THE PROCEDURE FOR THEIR PREPARATION AND FORMULATIONS SUITABLE FOR THE ORAL ADMINISTRATION CONTAINING THE PRODUCTS | |
CA2438509A1 (en) | Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria | |
EP1219296A4 (en) | Sebum production inhibitors | |
WO2002009717A1 (en) | Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient | |
EP1374868A4 (en) | Remedies and/or preventives for diabetic ischemic heart diseases | |
CA2394471A1 (en) | External preparation for treating pruritus | |
EP1149832A4 (en) | Benzamide derivatives and drugs containing the same | |
DE3476160D1 (en) | Derivatives of benzoic acid for use as a medicament and use of these derivatives as conserving or disinfecting agent | |
TW280810B (en) | ||
AU5243293A (en) | Nonatetraenoic acid derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030618 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050131 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07J 7/00 B Ipc: 7A 61P 27/16 B Ipc: 7A 61P 11/06 B Ipc: 7A 61K 31/573 B Ipc: 7A 61K 31/57 A Ipc: 7C 07J 5/00 B |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20050208 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOMEDIX CO., LTD |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HISAMITSU MEDICAL CO., LTD. |
|
17Q | First examination report despatched |
Effective date: 20050720 |
|
RTI1 | Title (correction) |
Free format text: PREVENTIVES/REMEDIES FOR INFLAMMATORY AIRWAY DISEASES |
|
17Q | First examination report despatched |
Effective date: 20050720 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NIPPON SHINYAKU CO., LTD. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20080604 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE |
|
REF | Corresponds to: |
Ref document number: 60134267 Country of ref document: DE Date of ref document: 20080710 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2305029 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20090303 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081231 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080528 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080528 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080829 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: NIPPON SHINYAKU CO., LTD. Free format text: NIPPON SHINYAKU CO., LTD.#14, KISSHOIN NISHINOSHO MONGUCHICHO, MINAMI-KU#KYOTO-SHI, KYOTO 601-8550 (JP) -TRANSFER TO- NIPPON SHINYAKU CO., LTD.#14, KISSHOIN NISHINOSHO MONGUCHICHO, MINAMI-KU#KYOTO-SHI, KYOTO 601-8550 (JP) |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20201113 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20201112 Year of fee payment: 20 Ref country code: SE Payment date: 20201211 Year of fee payment: 20 Ref country code: DE Payment date: 20201208 Year of fee payment: 20 Ref country code: AT Payment date: 20201125 Year of fee payment: 20 Ref country code: GB Payment date: 20201210 Year of fee payment: 20 Ref country code: DK Payment date: 20201210 Year of fee payment: 20 Ref country code: CH Payment date: 20201215 Year of fee payment: 20 Ref country code: PT Payment date: 20201221 Year of fee payment: 20 Ref country code: FI Payment date: 20201209 Year of fee payment: 20 Ref country code: IT Payment date: 20201110 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20201116 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20210119 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60134267 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20211220 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Expiry date: 20211221 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20211220 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: MAE |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20211230 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20211220 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MK Effective date: 20211221 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 396733 Country of ref document: AT Kind code of ref document: T Effective date: 20211221 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220405 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20211222 |